Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Geveko Markings and Solix Group in acquisition financing
Mandate

Vinge advises Geveko Markings and Solix Group in acquisition financing

December 21, 2020 Banking and Finance Automotive, Mobility and Electrification

Vinge advises Geveko Markings and Solix Group in collection with the debt financing of Geveko Markings’ acquisition of Oré Peinture with subsidiaries. The acquisition is the biggest in Geveko Markings’ almost 100-year history. Geveko Marking is a portfolio company of the Swedish investment firm Solix Group.

Vinge’s team was led by Henrik Ossborn who was assisted by Jack Bengtsson (Banking & Finance).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026